A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors Meeting Abstract
| Authors: | Rizvi, N. A.; Infante, J. R.; Gibney, G. T.; Bertino, E. M.; Cooley, S. A.; Lekatis, K.; Wigginton, J. M.; Gutierrez, A. A.; Gupta, A. K.; Kim, S. Y.; Hodi, F. S. |
| Abstract Title: | A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419605400 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.TPS3106 |
| Notes: | Meeting Abstract: TPS3106 -- Source: Wos |
